Epidemiology and impact of myalgic encephalomyelitis and chronic fatigue syndrome (ME/CFS) in Canada: A multi-centre population-based study
- Funded by Canadian Institutes of Health Research (CIHR)
- Total publications:0 publications
Grant number: 504834
Grant search
Key facts
Disease
COVID-19start year
2024Known Financial Commitments (USD)
$74,271.6Funder
Canadian Institutes of Health Research (CIHR)Principal Investigator
Nacul LuisResearch Location
CanadaLead Research Institution
University of British ColumbiaResearch Priority Alignment
N/A
Research Category
Secondary impacts of disease, response & control measures
Research Subcategory
Indirect health impacts
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
Myalgic encephalomyelitis (also known as chronic fatigue syndrome or ME/CFS) is a disabling illness. The causes of ME/CFS are not well understood. Getting a diagnosis can be challenging, and there are limited effective treatments. Patients report barriers to care and many unmet health needs. The true burden of ME/CFS is unknown but has increased since the COVID-19 pandemic. This is because some people develop persistent symptoms after COVID-19 infection (also known as Long COVID). Some Long COVID cases are indistinguishable from ME/CFS. Data on ME/CFS in Canada are scarce. Without this data, issues for people with ME/CFS persist. This project will accelerate the collection and understanding of data on ME/CFS. The goal is to characterize the ME/CFS population and evaluate their unmet needs. Our analysis includes people with ME/CFS due to Long COVID. First, we will produce an accurate database of people with ME/CFS using multiple methods. Second, we will estimate the number of people living with ME/CFS in Canada. Third, we will compare ME/CFS "cases" with controls. Fourth, we will investigate healthcare needs, inequities, and access to care for people with ME/CFS. We will use a national database called CanPath to access data from 3 provinces: British Columbia, Ontario, and Quebec. We will use standardized questionnaires to confirm the diagnosis of ME/CFS. We will compare disease severity and quality of life between ME/CFS cases and controls. We will also compare pre-pandemic ME/CFS cases with COVID-19-related cases of ME/CFS. We will also describe the journey people take to find health care and public services. The project includes people with lived experience of ME/CFS and Long COVID. The findings will provide a better understanding of the severity and burden of ME/CFS in Canada. This will be meaningful for the assessment and planning of health services. This will inform the development of needs-based health policies and interventions.